Title
Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia Effects of bezafibrate therapy
Author
TNO Preventie en Gezondheid
de Man, F.H.A.F.
Jonkers, I.J.A.M.
Schwedhelm, E.
Smelt, A.H.M.
Onkenhout, W.
van Duyvenvoorde, W.
Buytenhek, R.
Leuven, J.A.G.
Troost, R.
van der Laarse, A.
Princen, H.M.G.
Publication year
2000
Abstract
Although there is evidence that hyperlipidemia and predominance of small dense low density lipoproteins (LDLs) are associated with increased oxidative stress, the oxidation status in patients with hypertriglyceridemia (HTG) has not been studied in detail. Therefore, we studied urinary levels of F2-isoprostanes (8-isoprostaglandin F(2α) and 2,3-dinor-5,6-dihydro-8-isoprostaglandin F(2α)) and susceptibility of very low density lipoproteins (VLDLs) and LDLs to oxidation ex vivo in 18 patients with endogenous HTG and 20 matched control subjects. In addition, the effects of 6 weeks of bezafibrate therapy were assessed in a double-blind, placebo-controlled, crossover trial. Urinary levels of F2-isoprostanes were similar in the HTG and normolipidemic group. Bezafibrate caused an increase in 8-isoprostaglandin F(2α) (762 ± 313 versus 552 ± 245 ng/24 h for bezafibrate and placebo therapy, respectively; P = 0.03), whereas 2,3-dinor-5,6-dihydro-8-isoprostaglandin F(2α) levels tended to be increased (1714 ± 761 versus 1475 ± 606 ng/24 h for bezafibrate and placebo therapy, respectively; P = 0.11). VLDLs and LDLs were more resistant to copper-induced oxidation in patients with HTG than in control subjects. Bezafibrate reversed the oxidation resistance to the normal range. In conclusion, these results indicate the following: (1) HTG is associated with normal in vivo oxidative stress and enhanced ex vivo resistance of lipoproteins to oxidation. (2) Bezafibrate reduces the resistance of lipoproteins to copper-induced oxidation and enhances oxidative stress in HTG patients. Chemicals / CAS 8 isoprostaglandin F2 alpha, 27415-26-5; bezafibrate, 41859-67-0; cholesterol, 57-88-5; copper, 15158-11-9, 7440-50-8.
Subject
Bezafibrate
F2-isoprostanes
Hypertriglyceridemia
LDL oxidation
VLDL oxidation
8 isoprostaglandin F2 alpha
bezafibrate
cholesterol
copper
isoprostane
lipoprotein
low density lipoprotein
very low density lipoprotein
adult
cholesterol blood level
clinical article
clinical trial
controlled clinical trial
controlled study
crossover procedure
double blind procedure
drug effect
fatty acid desaturation
female
human
hyperlipidemia
hypertriglyceridemia
lipid oxidation
male
oxidative stress
priority journal
randomized controlled trial
urine level
To reference this document use:
http://resolver.tudelft.nl/uuid:f37a993d-55e5-4a8a-9452-a99c55c28c79
DOI
https://doi.org/10.1161/01.atv.20.11.2434
TNO identifier
953523
ISSN
1079-5642
Source
Arteriosclerosis, Thrombosis, and Vascular Biology, 20 (20), 2434-2440
Document type
article